- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01108276
Comparing the Efficacy of the ConvaTec Engenex® Negative Pressure Wound Therapy Device to Moist Wound Therapy
8. marts 2012 opdateret af: John Steinberg, DPM, Georgetown University
A Prospective, Randomized, Controlled Study Comparing the Efficacy of the ConvaTec Engenex® Negative Pressure Wound Therapy (NPWT) Device to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Wounds
This is an investigator-initiated prospective, randomized, controlled study.
Hypothesis/Objective: The study will evaluate the rates of wound healing among patients with lower extremity diabetic wounds comparing two groups of patients.
Group 1, the control group, will be treated with the standard of care treatment of moist wound therapy.
Group 2 will be treated with ConvaTec Engenex® NPWT.
Both groups will be treated in the inpatient and outpatient setting.
It is expected that the NPWT device will be an effective therapy that expedites time to closure and demonstrates a significant decrease in the size and depth of the wound over the course of the 12 week therapy as compared to the standard of care.
Studieoversigt
Status
Trukket tilbage
Intervention / Behandling
Detaljeret beskrivelse
After determining if you meet the criteria to be included in the study, your wound will be debrided (cleansed of any dead tissue or infection).
You will then be randomly placed into one of two treatment groups.
Group 1 will be the control group and a moist wound therapy will be applied to the wound.
Either you or home nursing will then change the dressing twice a week.
Group 2 will have a negative pressure wound therapy (NPWT) dressing applied.
The NPWT dressing will be changed twice a week by home nursing.
You will return to clinic every 2 weeks for a total of 12 weeks for observation and assessment of the diabetic foot ulcer.
If wound healing occurs prior to 12 weeks, a final assessment visit will be done and the status of the healed ulcer will be assessed.
Undersøgelsestype
Interventionel
Fase
- Fase 4
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Subject is 18 years of age or older
- Subjects with chronic lower extremity diabetic wounds, with or without a previous history of partial foot amputation.
- Subject has Diabetes Mellitus (type 1 or type 2)
- University of Texas Classification 1A-3A or 1B-3B
- Ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study.
Exclusion Criteria:
- Subjects < 18 years of age
- Subject is non-diabetic
- Subjects who present with wounds of etiology other than diabetes
- Subject demonstrates increased signs of clinical infection
- Has active malignant disease of any kind. A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry.
- University of Texas Classification 1C-3C
- Subjects participating in any other trials in regards to the diabetic foot ulcer.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall decrease in wound size
Tidsramme: 12 weeks
|
Overall decrease in wound size, summary statistics will be performed comparing both study groups.
|
12 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: John Steinberg, DPM, Georgetown University Hospital
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. maj 2010
Primær færdiggørelse (Forventet)
1. maj 2011
Studieafslutning (Forventet)
1. november 2011
Datoer for studieregistrering
Først indsendt
20. april 2010
Først indsendt, der opfyldte QC-kriterier
20. april 2010
Først opslået (Skøn)
21. april 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
9. marts 2012
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
8. marts 2012
Sidst verificeret
1. marts 2012
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2010-071
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .